DBV DBV Technologies SA

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021

Monthly information regarding the total number of voting rights and

total number of shares of the Company as of August 31, 2021

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

 

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345





Date



Total number of shares Total number of voting rights
08/31/202155,011,687



Total gross of voting rights: 55,011,687







Total net* of voting rights: 54,963,687



* Total net = total number of voting rights attached to shares – shares without voting rights

 

 

 

 

Attachment



EN
08/09/2021

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board ...

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by...

October 30, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein d...

DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration Châtillon, France, 30 octobre 2025 DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la « Société » ou « DBV »), une société biopharmaceutique au stade clinique, a annoncé ce jour la nomination provisoire d’une nouvelle administratrice indépendante, le Docteur Philina Lee, au sein de son Conseil d’administration (le « Conseil »), effective à compter du 30 octob...

October 30, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientif...

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled “Harnessing Immune Plasticity to Alte...

October 30, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies participe au congrès scientifique annuel de l'ACAAI

DBV Technologies participe au congrès scientifique annuel de l'ACAAI Châtillon, France, le 30 octobre 2025 DBV Technologies participe au congrès scientifique annuel de l'ACAAI DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – CUSIP : 23306J309) une société biopharmaceutique en phase clinique, a annoncé sa participation au congrès scientifique annuel 2025 de l'American College of Allergy, Asthma & Immunology (ACAAI), qui se tiendra du 6 au 10 novembre à Orlando, en Floride. DBV organisera un forum produit intitulé « Harnessing Immune Plasticity to Alt...

October 30, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Sale of approximately $30 million of ADSs T...

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares...

October 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch